One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Therapeutic drug monitoring: applying the ‘Goldilocks Principle’ to clinical pharmacology
Peter E Penson & Alice P McCloskey
doi : 10.1080/17512433.2023.2242161
Expert Review of Clinical Pharmacology, Volume 16, Issue 8 (2023)
Dried blood spot sampling for therapeutic drug monitoring: challenges and opportunities
Isadora Ritter Müller, Gabriel Linden, Mariele Feiffer Char?o, Marina Venzon Antunes & Rafael Linden
doi : 10.1080/17512433.2023.2224562
The use of dried blood spots (DBS) has gained interest in the field of therapeutic drug monitoring (TDM) due to its potential advantages, such as minimally invasive capillary blood collection, potential stabilization of drugs and metabolites at room or high temperatures, and lower biohazard, allowing for inexpensive storage and transportation.
Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes
Gavin Matthew Joynt, Lowell Ling, Wai Tat Wong & Jeffrey Lipman
doi : 10.1080/17512433.2023.2194629
The importance of antibiotic treatment for sepsis in critically ill septic patients is well established. Consistently achieving the dose of antibiotics required to optimally kill bacteria, minimize the development of resistance, and avoid toxicity is challenging. The increasing understanding of the pharmacokinetic and pharmacodynamic (PK/PD) characteristics of antibiotics, and the effects of critical illness on key PK/PD parameters, is gradually re-shaping how antibiotics are dosed in critically ill patients.
Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks
Siân Bentley, Jamie Cheong, Nikesh Gudka, Sukeshi Makhecha, Simone Hadjisymeou-Andreou & Joseph F Standing
doi : 10.1080/17512433.2023.2238597
Medicine use in children with cystic fibrosis (CF) is complicated by inconsistent pharmacokinetics at variance with the general population, a lack of research into this and its effects on clinical outcomes. In the absence of established dose regimens, therapeutic drug monitoring (TDM) is a clinically relevant tool to optimize drug exposure and maximize therapeutic effect by the bedside. In clinical practice though, use of this is variable and limited by a lack of expert recommendations.
Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring
Qiu-Yue Li, John van den Anker, Yue-E Wu, Guo-Xiang Hao & Wei Zhao
doi : 10.1080/17512433.2023.2181161
Infants and immunocompromised children with cytomegalovirus (CMV) infection have significant morbidity and mortality. Ganciclovir (GCV) and its oral prodrug valganciclovir (VGCV) are the major antiviral options of choice for the prophylaxis and treatment of CMV infection.
Predicting plasma concentration of quetiapine in patients with depression using machine learning techniques based on real-world evidence
Lin Yang, Jinyuan Zhang, Jing Yu, Ze Yu, Xin Hao, Fei Gao & Chunhua Zhou
doi : 10.1080/17512433.2023.2238604
We develop a model for predicting quetiapine levels in patients with depression, using machine learning to support decisions on clinical regimens.
Predicting busulfan exposure in patients undergoing hematopoietic stem cell transplantation using machine learning techniques
Dandan Li, Jingtong Zhao, Baohua Xu, You Zheng, Maobai Liu, Huiping Huang, Song Han & Xuemei Wu
doi : 10.1080/17512433.2023.2226866
This study aimed to establish an optimal model to predict the busulfan (BU) area under the curve at steady state (AUCss) by using machine learning (ML).
A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia
Anshul Vagrecha, Vincent Tao, Rosemarie Corless, Cassandra Colon, Arlene Redner & Mark Atlas
doi : 10.1080/17512433.2023.2223970
Pegylated form of E. coli derived asparaginase (PEG) is a crucial component of pediatric ALL therapy. Patients who develop a hypersensitivity (HSR) reaction with PEG receive an alternative form – Erwinia asparaginase (EA). However, an international shortage in 2017 had made it challenging to treat these patients. We have developed a comprehensive strategy to address this need.
